[PharmaEssentia] Announcement of the Board of Directors' Approval of the Q1 2026 Consolidated Financial Report
NQ Score
0/100
N1 Content Completeness
5
AI Summary (NQ-processed)
PharmaEssentia's Board of Directors approved its Q1 2026 consolidated financial report (January 1 to March 31, 2026). The company reported strong financial results with cumulative operating revenue of NTD 5,121,378 thousand, net profit of NTD 2,149,627 thousand, and basic earnings per share of NTD 5.79.